StreetInsider.com News Articles

Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

Fri, 21 Aug 2026 04:03:00 -0400

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the latest clinical data on its novel epidermal growth factor receptor (EGFR) inhibitor ZEGFROVY^® (sunvozertinib) in non-small cell lung cancer (NSCLC) will be presented at the 2026 World Conference on Lung Cancer (WCLC) from September 12 to 15 in Seoul, Republic of Korea.

Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

Fri, 21 Aug 2026 04:03:00 -0400

Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

Fri, 21 Aug 2026 04:03:00 -0400

Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

Fri, 21 Aug 2026 04:03:00 -0400

Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

Fri, 21 Aug 2026 04:03:00 -0400

Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

Fri, 21 Aug 2026 04:03:00 -0400

Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

Fri, 21 Aug 2026 04:03:00 -0400

Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

Fri, 21 Aug 2026 04:03:00 -0400

Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

Fri, 21 Aug 2026 04:03:00 -0400

Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

Fri, 21 Aug 2026 04:03:00 -0400

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Sat, 30 May 2026 20:09:00 -0400

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI
In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib, a JAK-only inhibitor, in combination with anti-PD-1 antibody enhanced anti-tumor response.

SHANGHAI, May 30, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, today announced the presentations of two studies in non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO)

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Sat, 30 May 2026 20:09:00 -0400

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI
In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib, a JAK-only inhibitor, in combination with anti-PD-1 antibody enhanced anti-tumor response.

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Sat, 30 May 2026 20:09:00 -0400

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI
In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib, a JAK-only inhibitor, in combination with anti-PD-1 antibody enhanced anti-tumor response.

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Sat, 30 May 2026 20:09:00 -0400

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI
In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib, a JAK-only inhibitor, in combination with anti-PD-1 antibody enhanced anti-tumor response.

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Sat, 30 May 2026 20:09:00 -0400

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI
In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib, a JAK-only inhibitor, in combination with anti-PD-1 antibody enhanced anti-tumor response.

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Sat, 30 May 2026 20:09:00 -0400

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI
In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib, a JAK-only inhibitor, in combination with anti-PD-1 antibody enhanced anti-tumor response.

Dizal's ZEGFROVY beats chemotherapy in lung cancer trial

Fri, 29 May 2026 08:52:56 -0400

Dizal Pharmaceutical (SSE: 688192) announced that its drug ZEGFROVY demonstrated superior results compared to platinum-doublet chemotherapy in treating patients with a specific type of non-small cell lung cancer, according to results from a phase 3 clinical trial.

The WU-KONG28 study evaluated ZEGFROVY as a first-line treatment for advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations. The trial included 324 patients randomized to receive either ZEGFROVY at 300 mg once daily or chemotherapy.

Median progression-free survival was 10.3 months with ZEGFROVY versus 7.5 months with chemotherapy. The objective response rate was 68.1% with ZEGFROVY compared to 35.4% with chemotherapy.

Dizal's ZEGFROVY beats chemotherapy in lung cancer trial

Fri, 29 May 2026 08:52:56 -0400

Median progression-free survival was 10.3 months with ZEGFROVY versus 7.5 months with chemotherapy. The objective response rate was 68.1% with ZEGFROVY compared to 35.4% with chemotherapy.

Dizal's ZEGFROVY beats chemotherapy in lung cancer trial

Fri, 29 May 2026 08:52:56 -0400

Median progression-free survival was 10.3 months with ZEGFROVY versus 7.5 months with chemotherapy. The objective response rate was 68.1% with ZEGFROVY compared to 35.4% with chemotherapy.

Dizal's ZEGFROVY beats chemotherapy in lung cancer trial

Fri, 29 May 2026 08:52:56 -0400

Median progression-free survival was 10.3 months with ZEGFROVY versus 7.5 months with chemotherapy. The objective response rate was 68.1% with ZEGFROVY compared to 35.4% with chemotherapy.

Dizal's ZEGFROVY beats chemotherapy in lung cancer trial

Fri, 29 May 2026 08:52:56 -0400

Median progression-free survival was 10.3 months with ZEGFROVY versus 7.5 months with chemotherapy. The objective response rate was 68.1% with ZEGFROVY compared to 35.4% with chemotherapy.

Dizal's ZEGFROVY beats chemotherapy in lung cancer trial

Fri, 29 May 2026 08:52:56 -0400

Median progression-free survival was 10.3 months with ZEGFROVY versus 7.5 months with chemotherapy. The objective response rate was 68.1% with ZEGFROVY compared to 35.4% with chemotherapy.

Dizal's ZEGFROVY beats chemotherapy in lung cancer trial

Fri, 29 May 2026 08:52:56 -0400

Median progression-free survival was 10.3 months with ZEGFROVY versus 7.5 months with chemotherapy. The objective response rate was 68.1% with ZEGFROVY compared to 35.4% with chemotherapy.

Dizal's ZEGFROVY beats chemotherapy in lung cancer trial

Fri, 29 May 2026 08:52:56 -0400

Median progression-free survival was 10.3 months with ZEGFROVY versus 7.5 months with chemotherapy. The objective response rate was 68.1% with ZEGFROVY compared to 35.4% with chemotherapy.

Dizal's ZEGFROVY beats chemotherapy in lung cancer trial

Fri, 29 May 2026 08:52:56 -0400

Median progression-free survival was 10.3 months with ZEGFROVY versus 7.5 months with chemotherapy. The objective response rate was 68.1% with ZEGFROVY compared to 35.4% with chemotherapy.